Bain-Owned Tanabe Pharma Targets Global Deals To Fuel Growth

Bain Capital-owned Tanabe Pharma Corp. is on the hunt for licensing deals abroad to bring medicines into Japan, betting that unmet patient demand and easing regulations will fuel growth.

A new team of around eight people in the US, in addition to an existing team in Japan, is sourcing therapies globally particularly in rare diseases, according to Akihisa Harada, Tanabe’s chief executive officer.